Guideline Recommendations for Treatment of Central Sleep Apnea in Adults

1. Initial Management Across All Etiologies

• Begin with a trial of CPAP (or bilevel PAP) to address any obstructive component before other interventions. This is recommended by the American Academy of Sleep Medicine as the first‑line approach for most patients with central sleep apnea. Conditional recommendation. 1
• If central events persist after an adequate CPAP trial, add oral acetazolamide. The American Academy of Sleep Medicine suggests this as a conditional recommendation with low certainty evidence. 2

2. Pharmacologic Therapy (Acetazolamide)

• Acetazolamide is advised for persistent CSA in a variety of etiologies (primary, medication‑induced, high altitude, and other medical conditions). Conditional recommendation, low‑to‑very‑low certainty evidence depending on the specific cause. 2
• In heart‑failure patients, acetazolamide may be used but requires routine electrolyte monitoring (2–4 weeks) because of the risk of arrhythmias. The American Academy of Sleep Medicine emphasizes this safety precaution. Low certainty. 3

3. Adaptive Servo‑Ventilation (ASV)

• ASV is recommended when CPAP fails, especially for treatment‑emergent CSA, because it improves quality of life and reduces daytime sleepiness. Conditional recommendation. 4
• For heart‑failure patients with preserved ejection fraction (HFpEF), ASV after a failed CPAP trial is considered safe and effective. Recommendation by the European Respiratory Society. 5
• In heart‑failure with mid‑range ejection fraction (LVEF 30‑45 %), ASV may be used only in expert centers with close monitoring and after optimization of cardiac therapy. Conditional recommendation. 6
• For severe systolic dysfunction (LVEF < 30 %), ASV should be limited to experienced centers, applied after optimal medical management and failed CPAP/oxygen trials, and may be considered in palliative‑care settings for highly symptomatic patients. Conditional recommendation. 1
• Modern ASV algorithms (post‑ADVENT‑HF) show no harm signal, contrasting with older SERVE‑HF devices that used fixed EPAP and minimal pressure support. Evidence from the European Respiratory Society. High certainty for safety of modern devices. 7

4. Etiology‑Specific Recommendations

4.1 Primary CSA & Treatment‑Emergent CSA

• Start with CPAP; if ineffective, add acetazolamide; consider ASV if central events remain uncontrolled. Conditional recommendations, low certainty. 1

4.2 CSA Due to Opioid Use

• Perform a CPAP trial before initiating ASV. Recommended by the European Respiratory Society. 4
• ASV is effective for opioid‑induced CSA and can be used without additional restrictions. Conditional recommendation, low certainty. 4
• Acetazolamide may be used as an adjunct when CPAP/ASV are insufficient. Conditional recommendation, low certainty. 2

4.3 CSA Due to High Altitude

• Low‑flow supplemental oxygen is first‑line for symptomatic patients. Conditional recommendation, very low certainty. 8
• Acetazolamide is an alternative pharmacologic option. Conditional recommendation, very low certainty. 2
• Patients with mild, transient symptoms may decline treatment, as many acclimate spontaneously; definitive therapy is descent to lower altitude. Recommendation by the American Academy of Sleep Medicine. 3

4.4 CSA Due to Other Medical Conditions

• Acetazolamide is suggested as a conditional therapy after optimization of the underlying disease. Low certainty evidence. 2

5. Safety Monitoring & Follow‑Up

• Electrolyte panels should be checked 2–4 weeks after initiating acetazolamide, especially in heart‑failure patients, to detect disturbances that could precipitate arrhythmias. American Academy of Sleep Medicine guidance. 3
• Re‑assessment of apnea‑hypopnea index, sleep quality, cardiac function, and adverse effects is advised at follow‑up visits after starting acetazolamide or ASV. 3

6. Common Pitfalls to Avoid

• Do not use ASV in patients with LVEF ≤ 45 % without proper selection and monitoring in expert centers. European Respiratory Society caution. 6
• Always optimize underlying cardiac therapy before initiating CSA‑specific treatments. American Academy of Sleep Medicine recommendation. 1
• Recognize that high‑altitude CSA may resolve spontaneously; unnecessary intervention should be avoided. 3

7. Treatment Hierarchy Summary

Central Sleep Apnea Management in Adults

Initial Device‑Based Therapy (American Academy of Sleep Medicine)

• Begin continuous positive airway pressure (CPAP) for every adult with central sleep apnea, irrespective of the underlying cause, to treat any co‑existing obstructive component and to stabilize breathing patterns. 9
• Prior to any CSA‑specific intervention, optimize treatment of the primary disorder (e.g., heart‑failure therapy, cessation or reduction of offending medications, management of neurological disease). 9

Pharmacologic Option (American Academy of Sleep Medicine)

• Acetazolamide is recommended as the first pharmacologic agent for patients whose central events persist after an adequate CPAP trial, applicable across primary, medication‑induced, treatment‑emergent, and other medical‑condition‑related CSA. 9

Adaptive Servo‑Ventilation (European Respiratory Society)

• Use adaptive servo‑ventilation (ASV) only after CPAP failure; safety and appropriateness are determined by left‑ventricular ejection fraction (LVEF). 10
• LVEF > 45 % (preserved or mildly reduced systolic function): ASV is safe and effective following CPAP failure. 10
• LVEF 30–45 % (mid‑range systolic function): ASV may be initiated only in expert centers with close monitoring after optimal cardiac therapy. 10
• LVEF < 30 % (severe systolic dysfunction): ASV is contraindicated except in palliative‑care settings at experienced centers when no alternative therapies are feasible. 10
• Modern ASV devices (post‑ADVENT‑HF era) have demonstrated no mortality signal, contrasting with earlier SERVE‑HF trial devices that employed fixed expiratory pressure and minimal pressure support. 10 – observational evidence
• Recent observational cohorts show reductions in major adverse cardiac events with ASV in subgroups characterized by longer nightly usage, preserved EF, or predominant obstructive events. 10 – moderate‑quality observational data

Bilevel Positive Airway Pressure (American Academy of Sleep Medicine)

• Bilevel PAP with a timed backup respiratory rate can be considered for patients with persistent CSA after CPAP failure across all etiologies. 9
• Bilevel PAP without a backup rate should be avoided for any CSA type because it offers no benefit over CPAP and may exacerbate central events. 9

Opioid‑Induced Central Sleep Apnea (European Respiratory Society)

• Start with a CPAP trial; if ineffective, progress to ASV. 10
• ASV is highly effective for opioid‑induced CSA and does not require restrictions beyond standard cardiac screening. 10

Safety Pitfalls and Clinical Priorities (American Academy of Sleep Medicine & European Respiratory Society)

• Do not employ ASV in patients with LVEF ≤ 45 % without selection and monitoring in expert centers; the SERVE‑HF trial showed increased mortality with older ASV algorithms in this population. 10
• Management should prioritize patient‑reported outcomes, sleep quality, and symptom relief rather than focusing solely on the elimination of respiratory events. 9
• If central events persist despite therapy, re‑evaluate underlying risk factors and consider alternative treatment modalities. 9

Consolidated Treatment Algorithm (American Academy of Sleep Medicine & European Respiratory Society)

All EF‑based recommendations are supported by European Respiratory Society evidence. 10

All facts are derived from peer‑reviewed guidelines and studies cited above; strength of evidence is indicated where reported.

Adaptive Servo‑Ventilation (ASV) in Central Sleep Apnea: Indications, Safety, and Outcomes

Indications for ASV

• Treatment‑emergent central sleep apnea (TE‑CSA) is the most common indication for ASV and should be started after an adequate CPAP trial fails to control central events. – European Respiratory Society 11
• Opioid‑induced central sleep apnea responds highly effectively to ASV after CPAP failure, requiring only standard cardiac screening. – European Respiratory Society 11
• Idiopathic (primary) central sleep apnea warrants ASV when CPAP does not control central events and symptoms persist. – European Respiratory Society 11
• Post‑stroke central sleep apnea can be treated with ASV after CPAP failure in symptomatic patients. – European Respiratory Society 11

Ejection‑Fraction‑Based Safety Algorithm

• LVEF > 45 % (HFpEF): ASV is safe and effective after a failed CPAP trial, with no restrictions beyond standard monitoring. – European Respiratory Society 11, 12
• LVEF 30–45 % (HFmrEF): ASV may be initiated only in expert centres, after optimisation of guideline‑directed medical therapy and close monitoring. – European Respiratory Society 11, 12
• LVEF < 30 % (severe systolic dysfunction): ASV is contraindicated except in palliative‑care settings at experienced centres when no alternative therapies are feasible. – European Respiratory Society 11, 12

Contraindications

• Absolute contraindication: heart failure with LVEF ≤ 45 % and predominant central sleep apnea when ASV is used outside expert centres or without proper patient selection. – American Academy of Sleep Medicine 11, 13
• Relative contraindications:
  
  • Severe systolic heart failure (LVEF < 30 %) except in palliative contexts at specialised centres. – European Respiratory Society 11
  • Inadequate CPAP trial before ASV initiation – CPAP must be attempted first across all aetiologies. – European Respiratory Society & American Academy of Sleep Medicine 11, 13
  • Suboptimal treatment of underlying disease; cardiac therapy must be optimised before initiating ASV. – European Respiratory Society 11

Device Settings and Titration

• EPAP should be titrated to eliminate any obstructive component before ASV pressure support is applied. – European Respiratory Society 11
• Modern ASV devices (post‑ADVENT‑HF era) employ variable EPAP and adaptive pressure support, unlike older fixed‑EPAP algorithms. – European Respiratory Society 11
• Target residual AHI < 5–10 events/hour, with elimination of central and any residual obstructive events. – European Respiratory Society 11
• Adequate nightly usage (≥ 4 h/night on > 70 % of nights) is linked to better outcomes, including reduced major adverse cardiac events. – European Respiratory Society 11

Treatment Algorithm Highlights

• Maximise guideline‑directed medical therapy for heart failure, adjust or discontinue offending medications (e.g., opioids), and manage comorbid neurological conditions before considering ASV. – American Academy of Sleep Medicine 13
• Begin CPAP for all central sleep apnea patients, regardless of aetiology, to treat co‑existing obstructive events and stabilise breathing. – American Academy of Sleep Medicine 13
• If CPAP fails, acetazolamide is the first pharmacologic option across CSA aetiologies. – American Academy of Sleep Medicine 13
• Bilevel PAP with a backup rate is an alternative to ASV after CPAP failure; bilevel PAP without a backup rate offers no benefit and may worsen central events. – American Academy of Sleep Medicine 13

Efficacy and Clinical Outcomes

• ASV is superior to medical therapy alone, acetazolamide, non‑invasive ventilation, neural stimulation, and nocturnal oxygen for suppressing central sleep apnea and Cheyne‑Stokes respiration. – European Respiratory Society (multiple RCTs) 11, 12
• Quality‑of‑life scores improve significantly with ASV across all forms of central sleep apnea. – European Respiratory Society 11
• Meta‑analysis of four randomised controlled trials shows no effect of ASV on mortality in heart‑failure patients with reduced ejection fraction and central sleep apnea, contradicting earlier SERVE‑HF findings. – American Academy of Sleep Medicine (Level A evidence) 13
• Observational cohorts demonstrate reductions in major adverse cardiac events in subgroups with longer nightly ASV usage, preserved ejection fraction, or predominant obstructive events. – European Respiratory Society 11
• Recent randomised trials and real‑world registries indicate that contemporary ASV devices have no adverse impact on hard cardiovascular endpoints. – European Respiratory Society 11, 12

Monitoring and Safety Follow‑Up

• Routine monitoring should include device‑generated data (AHI, central apnea index, leak, nightly usage), patient‑reported outcomes (Epworth Sleepiness Scale, quality‑of‑life questionnaires), and, in heart‑failure patients, echocardiographic parameters and exercise capacity. – American Academy of Sleep Medicine & European Respiratory Society 13, 11
• Close cardiovascular follow‑up is recommended for patients with LVEF 30–45 % receiving ASV at expert centres. – European Respiratory Society 11

Key Clinical Takeaway

• ASV should be reserved for patients with symptomatic central sleep apnea who have failed CPAP; safety is determined by left ventricular ejection fraction: unrestricted use when LVEF > 45 %, expert‑centre‑only use when LVEF 30–45 %, and contraindicated when LVEF < 30 % except for palliative care. – European Respiratory Society 11